HK1199616A1 - Cachexia treatment - Google Patents

Cachexia treatment

Info

Publication number
HK1199616A1
HK1199616A1 HK14113143.3A HK14113143A HK1199616A1 HK 1199616 A1 HK1199616 A1 HK 1199616A1 HK 14113143 A HK14113143 A HK 14113143A HK 1199616 A1 HK1199616 A1 HK 1199616A1
Authority
HK
Hong Kong
Prior art keywords
cachexia treatment
cachexia
treatment
Prior art date
Application number
HK14113143.3A
Other languages
English (en)
Chinese (zh)
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of HK1199616A1 publication Critical patent/HK1199616A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK14113143.3A 2011-09-23 2014-12-31 Cachexia treatment HK1199616A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
PCT/US2012/056492 WO2013043973A2 (fr) 2011-09-23 2012-09-21 Traitement de la cachexie

Publications (1)

Publication Number Publication Date
HK1199616A1 true HK1199616A1 (en) 2015-07-10

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113143.3A HK1199616A1 (en) 2011-09-23 2014-12-31 Cachexia treatment

Country Status (16)

Country Link
US (2) US9809649B2 (fr)
EP (1) EP2750709B1 (fr)
JP (1) JP6204915B2 (fr)
KR (1) KR102039198B1 (fr)
CN (2) CN108404127A (fr)
AU (1) AU2012312225B2 (fr)
CA (1) CA2849710C (fr)
DK (1) DK2750709T3 (fr)
ES (1) ES2695102T3 (fr)
HK (1) HK1199616A1 (fr)
IL (1) IL231622B (fr)
MX (1) MX356808B (fr)
PT (1) PT2750709T (fr)
RU (1) RU2622021C2 (fr)
WO (1) WO2013043973A2 (fr)
ZA (1) ZA201402057B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2140469T3 (es) 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (fr) 1993-11-23 1995-06-28 Schering-Plough Anticorps monoclonaux humains contre des cytokines humains et méthode de fabrication de tels anticorps
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
US20040086507A1 (en) 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7211602B2 (en) 2001-11-16 2007-05-01 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
TWI347951B (en) 2002-09-06 2011-09-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (fr) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Analogues de migrastatine utilises dans le traitement du cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
EP1819359B1 (fr) 2004-12-09 2015-03-18 Janssen Biotech, Inc. Immunoconjugues anti-integrines, methodes pour leur production et leur application
CN109187944A (zh) 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2006298767B2 (en) 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
US20100047204A1 (en) 2006-04-14 2010-02-25 Dana Sue Yoo Use of organic compounds
AU2007251239B2 (en) 2006-05-15 2013-08-22 Xbiotech Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
PT2109623E (pt) 2006-05-22 2012-01-12 Xbiotech Inc Tratamento de cancro com anticorpos anti-il-1
EP2446904B1 (fr) 2006-05-30 2015-04-29 Genentech, Inc. Anti-CD22 anticorps, immuno-conjugués et utilisations associées
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
EP3632444A3 (fr) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Antagonistes lfa-1 topiques pour une utilisation dans le traitement localisé de troubles immunitaires associés
MX2010012963A (es) 2008-05-30 2011-04-05 Xbiotech Inc Anticuerpos de interleucina-1 alfa y metodos de uso.
CN102209557A (zh) 2008-09-12 2011-10-05 埃克斯生物科技公司 靶向病原性单核细胞
PE20120586A1 (es) 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
JP2013507929A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
WO2014055541A1 (fr) 2012-10-04 2014-04-10 Xbiotech, Inc. Traitement d'affections psychiatriques
CA2886747C (fr) 2012-10-04 2023-12-05 Xbiotech Inc. Traitement des maladies vasculaires et de leurs complications

Also Published As

Publication number Publication date
US9809649B2 (en) 2017-11-07
DK2750709T3 (en) 2018-12-03
JP2014526559A (ja) 2014-10-06
AU2012312225A1 (en) 2014-04-10
EP2750709A2 (fr) 2014-07-09
MX356808B (es) 2018-06-14
CA2849710A1 (fr) 2013-03-28
JP6204915B2 (ja) 2017-09-27
ZA201402057B (en) 2016-08-31
CN103906536A (zh) 2014-07-02
RU2622021C2 (ru) 2017-06-08
CA2849710C (fr) 2020-04-28
US20180037647A1 (en) 2018-02-08
AU2012312225B2 (en) 2017-10-05
PT2750709T (pt) 2018-11-22
ES2695102T3 (es) 2019-01-02
US10202449B2 (en) 2019-02-12
IL231622A0 (en) 2014-05-28
EP2750709B1 (fr) 2018-08-15
IL231622B (en) 2018-10-31
KR102039198B1 (ko) 2019-10-31
MX2014003402A (es) 2015-03-05
CN108404127A (zh) 2018-08-17
WO2013043973A2 (fr) 2013-03-28
KR20140078690A (ko) 2014-06-25
RU2014111662A (ru) 2015-10-27
EP2750709A4 (fr) 2015-06-10
US20130078258A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
EP2611496A4 (fr) Procédés de traitement
PL2652193T3 (pl) Obróbka
HK1199616A1 (en) Cachexia treatment
GB2487248B (en) Water treatment
GB2494275B (en) Turf treatment
GB2487246B (en) Water treatment
GB2487247B (en) Water treatment
GB201013573D0 (en) Treatment
ZA201307760B (en) Treatment regimens
GB2487249B (en) Water treatment
HUE047357T2 (hu) Gyógyászati kezelés
ZA201308117B (en) Avian-based treatment
GB2487262B (en) Turf treatment
GB201014097D0 (en) Treatment
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102284D0 (en) Treatment
GB201102269D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102265D0 (en) Treatment

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE APPLICANT/PROPRIETOR: FROM "XBIOTECH, INC" TO "XBIOTECH INC."